| ACE | angiotensin convertase enzyme |
| ACE2 | angiotensin-converting enzyme-2 |
| ACEi | angiotensin-converting enzyme inhibitors |
| ADAM-17 | short for a disintegrin and metalloproteinase domain 17 |
| Ang- | angiotensin |
| ARB | angiotensin receptor blockers |
| ARDS | acute respiratory stress syndrome |
| AT1R | Angiotensin receptor type-I |
| AT2R | Angiotensin receptor type-II |
| ATCO | Angiotensin-(1,7) Treatment in COVID-19 |
| BH4 | coenzyme tetrahydrobiopterin |
| CAD | coronary artery disease |
| CK | creatine kinase |
| COVID-19 | Coronavirus disease 2019 |
| cTnI | cardiac troponin-I |
| DIC | disseminated intravascular coagulation |
| EMMPRIN-CD147 | extracellular matrix metalloproteinase inducer |
| HDL-C | high-density lipoprotein-cholesterol |
| HPβCD-Ang-(1-7) | hydroxypropyl β-cyclodextrin-Ang-(1-7) |
| IFN-γ | interferon gamma |
| IP-10 | IFN-γ-induced protein-10 |
| LDL-C | low-density lipoprotein-cholesterol |
| MasR | Mas receptor |
| MCP-1 | Monocyte chemoattractant protein-1 |
| MERS | Middle East Respiratory Syndrome coronavirus |
| Mrg-D | Mas-related receptor |
| NEP | Neprilysin |
| NF-κB | nuclear factor-κB |
| NLRP3 | NOD-, LRR- and pyrin domain-containing protein-3 |
| NOD | Nucleotide-binding and oligomerization domain |
| NT-proBNP | N-terminal pro-B-type natriuretic peptide |
| PAI-1 | plasminogen activator inhibitor type-1 |
| RAAS | renin-angiotensin-aldosterone system |
| ROS | reactive oxidant species |
| sACE2 | Soluble ACE2 |
| SARS-CoV-1 | Severe acute respiratory syndrome coronavirus-1 |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus-2 |
| SNPs | single nucleotide polymorphisms |
| TC | total colesterol |
| TG | triglycerides |
| TMPRSS2 | serine protease transmembrane serine protease-2 |
| TNF-α | Tumor necrosis factor-alpha |